Bupacon is a Buparvaquone injection with fast and longer duration of action. It is active against both the schizont and piroplasm stages. It is used for phophylaxis and treatment of theileriosis.
Buparvaquone is a second-generation hydroxynaphthoquinone related to parvaquone, with novel features that make it a promising compound for the therapy and prophylaxis of all forms of theileriosis. It has been tested extensively against Theileria annulata, T. parva and T. sergenti, both in laboratory studies and in field trials, and it has undergone a rigorous programme of toxicology and safety studies. Formulated as a solution for intramuscular injection, it offers a safe and convenient alternative to existing antitheilerial products
Buparvaquone was selected for development using the following three principal criteria:
- In vitro activity: EC50 of 0.0003 mg/L (10-9M) against Theileria parva · Long plasma half-life (at least 7 days)
- Low toxicity: oral LD50 in rats > 8000 mg/kg
The high in vitro activity against T. parva (Muguga) E174 and the persistence in plasma following intramuscular injection may both be related to the tertiary-butyl moiety in the buparvaquone molecule, which results in far slower metatolism to the hydroxy derivative at the 4-position on the cyclohexyl ring (Figure 1). Parvaquone, which is much more readily metabolized, has an EC50 of 0.006 mg/L (1.3 × 10-8M) and persists in plasma for only about two days. A high-pressure liquid chromatography study (Kinabo and Bogan, 1988) confirms that buparvaquone persists longer in plasma than parvaquone. Acute oral toxicity in the rodent is similarly very low (> 8000 mg/kg) for both compounds.
Trueace Inj. is indicated for the treatment of theileriosis (Corridor disease, East Coast Fever, Tropical Theileriosis, etc.) in cattle caused by Theileria annulata and T. orientalis (sergenti). It is active against both the schizont and piroplasm stages of Theileria species and may be used in the incubation period of the disease, or when clinical signs are apparent.
Antiprotozoa for intramuscular injection which offers a safe and convenient alternative to existing antitheilerial products.
For the treatment of theileriosis (East Coast Fever, January Disease, Corridor disease, Tropical theileriosis etc) in cattle caused by Theileria parva, T. annulata, T. mutans, and T. orientalis.
Active against both the schizonts and piroplasms stages of Theileria and may be used during the incubation period of the disease or when clinical signs are apparent.
Mechanism of Action
There is no apparent adverse effect on the structure of host lymphocytes, including mitochondria, which emphasizes the parasite-specificity of the mode of action of buparvaquone. It may also help to explain the narrow spectrum of action of the compound, which is confined to certain sporozoan parasites
Intra-muscular Injection bioavaibility is approximately 3% mg/L after 3 hours and 17 minutes. Volume of distribution occur slowly and elimination half life approximately 26 hours and 44 minutes.
- It is a tick-borne disease
- Fever – 105-107.f
- lymph node enlargement
- nasal discharge
- lacrimal discharge
- off feed
- low milk production.
- Intravenouse and subcoutaneus injection are forbidden.
- Vaccinate after clinical improvement
- Use antibiotic to control second infectious.